STOCK TITAN

Rapport Therapeutics, Inc. - RAPP STOCK NEWS

Welcome to our dedicated page for Rapport Therapeutics news (Ticker: RAPP), a resource for investors and traders seeking the latest updates and insights on Rapport Therapeutics stock.

Rapport Therapeutics, Inc. (RAPP) is a clinical-stage biopharmaceutical company committed to the discovery and development of transformational small-molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's unique approach is rooted in its foundational science, which has elucidated the complexities of neuronal receptor biology. This allows Rapport Therapeutics to map and target specific neuronal receptor complexes effectively.

Neuronal receptors are intricate assemblies comprising receptor principal subunits and receptor-associated proteins (RAPs). These RAPs play a significant role in regulating receptor expression and function. Rapport Therapeutics leverages this insight to advance its RAP technology platform, enabling the creation of precision small molecule product candidates. This strategy holds the promise of overcoming many of the limitations faced by conventional neurology drug discovery efforts.

The company's precision neuroscience pipeline includes its lead clinical program, RAP-219. This program is designed to achieve neuroanatomical specificity by selectively targeting a RAP expressed in discrete regions of the brain. RAP-219 is currently undergoing clinical trials focused on treating focal epilepsy, peripheral neuropathic pain, and bipolar disorder. Additionally, Rapport Therapeutics is engaged in other preclinical and late-stage discovery programs targeting CNS disorders such as chronic pain and hearing disorders.

Recently, Rapport Therapeutics successfully closed its initial public offering (IPO) with joint book-running managers Goldman Sachs & Co. LLC, Jefferies, TD Cowen, and Stifel. In addition to the IPO, the company sold 1,058,824 shares of common stock in a concurrent private placement to existing stockholders. The gross proceeds from these transactions, before deducting relevant expenses, amounted to approximately $174 million. These funds are expected to support the continued advancement of the company's clinical and preclinical programs.

Rhea-AI Summary

Rapport Therapeutics, a clinical-stage biotechnology firm specializing in central nervous system disorder treatments, closed its initial public offering (IPO) on June 12, 2024. The IPO involved 9,200,000 shares of common stock at $17.00 per share, totaling approximately $174 million, including the full exercise of the underwriters' option to purchase additional shares and a concurrent private placement. Trading began on June 7, 2024, under the ticker symbol 'RAPP'. Goldman Sachs, Jefferies, TD Cowen, and Stifel managed the offering. The concurrent private placement involved selling 1,058,824 shares to existing stockholders. The proceeds will be used to further Rapport's development of small molecule medicines.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.41%
Tags
IPO private placement offering
-
Rhea-AI Summary

Rapport Therapeutics, a clinical-stage biotech company, announced the pricing of its IPO at $17.00 per share for 8 million shares. Trading on the Nasdaq under the symbol 'RAPP' begins June 7, 2024, with the offering expected to close on June 10, 2024. Additionally, the company offers a 30-day option for underwriters to purchase up to 1.2 million more shares. Concurrently, Rapport will sell 1,058,824 shares in a private placement at the IPO price. Combined, these transactions aim to raise approximately $154 million before expenses, contingent on customary closing conditions. Joint book-running managers include Goldman Sachs, Jefferies, TD Cowen, and Stifel.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags

FAQ

What does Rapport Therapeutics, Inc. do?

Rapport Therapeutics is a clinical-stage biopharmaceutical company focused on developing small-molecule medicines for central nervous system (CNS) disorders.

What is the RAP technology platform?

The RAP technology platform enables Rapport Therapeutics to create precision small molecule candidates by targeting specific neuronal receptor complexes.

What is RAP-219?

RAP-219 is Rapport Therapeutics' lead clinical program aimed at treating focal epilepsy, peripheral neuropathic pain, and bipolar disorder.

Who managed Rapport Therapeutics' initial public offering (IPO)?

Goldman Sachs & Co. LLC, Jefferies, TD Cowen, and Stifel acted as joint book-running managers for the IPO.

How much did Rapport Therapeutics raise in its IPO and concurrent private placement?

The company raised approximately $174 million before deducting underwriting discounts, commissions, and other expenses.

What is the focus of Rapport Therapeutics' current clinical trials?

The current clinical trials are focused on treating focal epilepsy, peripheral neuropathic pain, and bipolar disorder.

What additional CNS disorders is Rapport Therapeutics researching?

Rapport Therapeutics is also researching treatments for chronic pain and hearing disorders.

What are receptor-associated proteins (RAPs)?

RAPs are proteins that play crucial roles in regulating the expression and function of neuronal receptors.

Who can I contact for more information about Rapport Therapeutics?

For more information, you can contact Julie DiCarlo, Head of Communications & IR at Rapport Therapeutics.

Where can I obtain a copy of the final IPO prospectus?

A copy of the final IPO prospectus can be obtained from Goldman Sachs & Co. LLC, Jefferies LLC, TD Securities (USA) LLC, or Stifel, Nicolaus & Company, Incorporated.

Rapport Therapeutics, Inc.

Nasdaq:RAPP

RAPP Rankings

RAPP Stock Data

711.77M
34.32M
6.54%
65.59%
0.66%
Biotechnology
Healthcare
Link
United States of America
Boston